BostonGene Raises $150M in Series B Funding
Summary
NEC Corporation (NEC; TSE: 6701) led the financing with participation from Impact Investment Capital and Japan Industrial Partners. The company intends to use the capital to scale growth, including continued innovation, clinical and research partnerships, and international expansion. Further, leveraging NEC’s infrastructure, BostonGene and NEC intend to form a joint venture to bring lifesaving solutions to patients in Japan and other Asian countries. Led by Andrew Feinberg, President, and CEO, BostonGene provides an innovative computational platform that performs AI-based molecular and immune profiling to discover correlations between tumor genomics, a patient’s immune system, and the effectiveness of all available approved and investigational treatments. BostonGene’s integrated model of tumor genetics, transcriptomics, microenvironment, and tumor composition provides a 360° overview of a patient tumor to give physicians invaluable insights into potential treatment options.